Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

Saad Usmani, Chief of MSK's Myeloma Service, says there are far more treatment options for multiple myeloma today compared with just 20 years ago. Note: This story was originally published in 2022 and ...

First Lady Louise ''Liza'' Araneta-Marcos has inspected the Coconut Palace and the Philippine International Convention Center in preparation for ASEAN 2026. The Philippines will be the chairman of the ...

Pomalyst (pomalidomide) is a prescription drug that’s used to treat multiple myeloma in adults. Pomalyst is also available as a generic drug. Pomalyst comes as an oral capsule. The active ...

its side effects After a diagnosis of multiple myeloma, the first type of treatment you receive — also called “upfront” or “front-line” therapy — now includes a promising new option. Research has ...

This will help determine the optimal sequence and combination regimen for treating relapsed/refractory multiple myeloma patients after CAR-T therapy relapse (124). Furthermore, with BCMA CAR-T now ...

including the first line. The multiple myeloma pipeline consists primarily of new drugs with established mechanisms of action that aim to outcompete existing agents, including BCMA-targeting ...

which is expected to demonstrate strong efficacy in treating later-line multiple myeloma. Early results have already indicated a high progression-free survival rate, surpassing that of competitors ...

Some people with multiple myeloma have no signs or symptoms at all. But sometimes multiple myeloma does cause symptoms, including bone pain or weakness, infections, low blood counts, or other problems ...

At the data cutoff point, 33.0% of patients in the Darzalex Faspro group and 52.0% of the active monitoring group had started first-line treatment for multiple myeloma. First launched in 2015 ...

Background: Multiple myeloma (MM), a malignant disease of plasma cells originating in the bone marrow, is influenced significantly by genetic factors. Although plasma liposomes have been linked to MM, ...